ArticleBMC cancer2026
Lung cancer treatment pathways in the largest private health insurance in Brazil: a real-world data study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the leading cause of cancer-related mortality in Brazil, yet few studies have characterized real-world treatment pathways within Brazil’s private supplementary health sector, which covers nearly 25% of the Brazilian population.
methodsWe conducted a retrospective cohort study including patients with biopsy-confirmed lung cancer treated between 2020 and 2024 within the Hapvida NotreDame Intermédica system, the largest private health insurer in Brazil. Demographic, clinical, treatment, and cost data were extracted from structured administrative and electronic medical record databases. Descriptive statistics, Kaplan–Meier survival analysis, and cost estimations (in Brazilian reais, adjusted by IPCA) were performed.
resultsA total of 690 patients were identified. Median age at diagnosis was 67 years, and 56.4% were women. Stage IV disease was most common (35.7%), while 32.5% had missing stage documentation. Adenocarcinoma predominated (64.5%), and surgical resection was performed in 37.5% of patients. Chemotherapy was administered in 64.9%, mostly with palliative intent, and radiotherapy in 48.8%. Hospitalization occurred in 78.5% of patients, and 36.4% required ICU admission. Median survival was significantly longer for patients with early-stage disease and for those who underwent surgery. Median direct healthcare costs increased with advancing stage, ranging from R$19,544 in stage I to R$75,837 in stage IV, with hospitalizations and surgeries as main cost drivers.
conclusionsThis large real-world cohort from Brazil’s private sector highlights the predominance of late-stage diagnoses, incomplete molecular testing, high rates of acute care utilization, and substantial costs associated with lung cancer. These findings complement previous Brazilian studies and underscore the need for earlier detection, expanded biomarker access, and cost-efficient strategies in supplementary healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.